Full Press Release Details
BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions.
BBIO
BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions
Key Takeaway: BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis